Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov;11(11):3107-3116.
doi: 10.1111/1759-7714.13611. Epub 2020 Sep 15.

Male breast cancer: A closer look at patient and tumor characteristics and factors associated with survival

Jing Zhao  1   2   3 , Bin Wang  1   2   3 , Jing Zhao  4 , Yiran Mao  4 , Jun Liu  1   2   3 , Yanfang Yang  1   2   3
Affiliations

Male breast cancer: A closer look at patient and tumor characteristics and factors associated with survival

Jing Zhao et al. Thorac Cancer. 2020 Nov.

Abstract

Background: The prognostic effect of molecular subtypes on male breast cancer (MBC) remains unclear. The aim of this study was to evaluate the clinicopathological and prognostic factors of MBC patients.

Methods: From 1 January 1990 to 31 December 2014, the data of 152 MBC and 304 female breast cancer (FBC) patients were identified and extensively compared.

Results: Compared with the FBC group, MBC patients were found to have a higher rate of cancer family history (30.9% vs. 18.4%, P = 0.001), mass around the areola area (37.5% vs. 5.6%, P = 0.000), lymph node invasion (44.1% vs. 34.2%, P = 0.006) and hormonal receptor positivity (66.4% vs. 49.3%, P = 0.027). Luminal A was the most common subtype accounting for 69.8%, whereas HER2-positive (12.7%) and TNBC (1.6%) subtypes were rare in the MBC group. However, it was significantly lower for MBC than for FBC who received endocrine therapy (38.8% vs. 49.3%, P = 0.041). MBC showed the worse overall survival (OS) and disease-free survival (DFS) than those of FBC patients. However, 10-year OS and DFS were similar between MBC and FBC patients in the subgroups of nonluminal subtype (P < 0.001), but worse in MBC patients than those in FBC patients in the subgroups of luminal A (P = 0.004 for OS; P = 0.002 for DFS) and luminal B (P = 0.006 for OS; P = 0.003 for DFS). Multivariate analysis indicated tumor size, radical mastectomy and endocrine therapy as independent risk factors for OS and DFS of MBC patients.

Conclusions: Our study determined that MBC patients possessed a worse prognosis, usually with lymph node invasion, and were estrogen receptor (ER), progesterone receptor (PR)-positive and human epidermal growth factor receptor (HER2)-negative. Molecular subtypes based on FBC did not provide the same prognostic information in MBC, even in the luminal groups.

Keywords: Clinical characteristic; male breast cancer; prognosis; therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comparison of overall outcome between MBC and FBC patients. (a) Overall survival (formula image) MBC, and (formula image) FBC; and (b) disease‐free survival (formula image) MBC, and (formula image) FBC.
Figure 2
Figure 2
Comparison of outcome between MBC and FBC patients within a matched nonluminal subtype. (a) Overall survival (formula image) MBC, and (formula image) FBC; and (b) disease‐free survival (formula image) MBC, and (formula image) FBC.
Figure 3
Figure 3
Comparison of outcome between MBC and FBC patients within a molecular subtype. Overall survival (OS) and disease‐free survival (DFS). (a) Luminal A group (formula image) MBC, and (formula image) FBC; (formula image) MBC, and (formula image) FBC. (b) Luminal B group (formula image) MBC, and (formula image) FBC; (formula image) MBC, and (formula image) FBC.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sarmiento S, McColl M, Musavi L et al Male breast cancer: A closer look at patient and tumor characteristics and factors that affect survival using the National Cancer Database. Breast Cancer Res Treat 2020; 180 (2): 471–9. 10.1007/s10549-020-05556-y. - DOI - PubMed
    1. Hassett MJ, Somerfield MR, Baker ER et al Management of male breast cancer: ASCO guideline. J Clin Oncol 2020; 38 (6):JCO1903120 10.1200/JCO.19.03120. - DOI - PubMed
    1. Korde LA, Zujewski JA, Kamin L et al Multidisciplinary meeting on male breast cancer: Summary and research recommendations. J Clin Oncol 2010; 28 (12): 2114–22. 10.1200/JCO.2009.25.5729. - DOI - PMC - PubMed
    1. Fentiman IS. The biology of male breast cancer. Breast 2018; 38: 132–5. 10.1016/j.breast.2018.01.001. - DOI - PubMed
    1. Abreu MH, Afonso N, Abreu PH et al Male breast cancer: Looking for better prognostic subgroups. Breast 2016; 26: 18–24. 10.1016/j.breast.2015.12.001. - DOI - PubMed

Publication types